167 related articles for article (PubMed ID: 26620718)
21. Discovery and structure-activity relationship studies of N-substituted indole derivatives as novel Mcl-1 inhibitors.
Luan S; Ge Q; Chen Y; Dai M; Yang J; Li K; Liu D; Zhao L
Bioorg Med Chem Lett; 2017 May; 27(9):1943-1948. PubMed ID: 28343875
[TBL] [Abstract][Full Text] [Related]
22. Discovery and development of substituted tyrosine derivatives as Bcl-2/Mcl-1 inhibitors.
Liu R; Liu L; Liu T; Yang X; Wan Y; Fang H
Bioorg Med Chem; 2018 Sep; 26(17):4907-4915. PubMed ID: 30170927
[TBL] [Abstract][Full Text] [Related]
23. Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivity.
Bruncko M; Wang L; Sheppard GS; Phillips DC; Tahir SK; Xue J; Erickson S; Fidanze S; Fry E; Hasvold L; Jenkins GJ; Jin S; Judge RA; Kovar PJ; Madar D; Nimmer P; Park C; Petros AM; Rosenberg SH; Smith ML; Song X; Sun C; Tao ZF; Wang X; Xiao Y; Zhang H; Tse C; Leverson JD; Elmore SW; Souers AJ
J Med Chem; 2015 Mar; 58(5):2180-94. PubMed ID: 25679114
[TBL] [Abstract][Full Text] [Related]
24. Discovery and biological characterization of potent myeloid cell leukemia-1 inhibitors.
Lee T; Bian Z; Zhao B; Hogdal LJ; Sensintaffar JL; Goodwin CM; Belmar J; Shaw S; Tarr JC; Veerasamy N; Matulis SM; Koss B; Fischer MA; Arnold AL; Camper DV; Browning CF; Rossanese OW; Budhraja A; Opferman J; Boise LH; Savona MR; Letai A; Olejniczak ET; Fesik SW
FEBS Lett; 2017 Jan; 591(1):240-251. PubMed ID: 27878989
[TBL] [Abstract][Full Text] [Related]
25. Targeting Myeloid Leukemia-1 in Cancer Therapy: Advances and Directions.
Deng H; Han Y; Liu L; Zhang H; Liu D; Wen J; Huang M; Zhao L
J Med Chem; 2024 Apr; 67(8):5963-5998. PubMed ID: 38597264
[TBL] [Abstract][Full Text] [Related]
26. Bcl-xl and Mcl-1 are the major determinants of the apoptotic response to dual PI3K and MEK blockage.
Jokinen E; Koivunen JP
Int J Oncol; 2015 Sep; 47(3):1103-10. PubMed ID: 26135106
[TBL] [Abstract][Full Text] [Related]
27. Discovery and development of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as Bcl-2/Mcl-1 inhibitors.
Liu R; Liu L; Yang X; Fang H
Bioorg Chem; 2019 Jul; 88():102938. PubMed ID: 31028992
[TBL] [Abstract][Full Text] [Related]
28. Drimane Derivatives as the First Examples of Covalent BH3 Mimetics that Target MCL-1.
Daressy F; Malard F; Seguy L; Guérineau V; Apel C; Dumontet V; Robert A; Groo AC; Litaudon M; Bignon J; Desrat S; Malzert-Fréon A; Wiels J; Lescop E; Roussi F
ChemMedChem; 2021 Jun; 16(11):1788-1797. PubMed ID: 33665938
[TBL] [Abstract][Full Text] [Related]
29. Norcantharidin enhances ABT-737-induced apoptosis in hepatocellular carcinoma cells by transcriptional repression of Mcl-1.
Zhang S; Li G; Ma X; Wang Y; Liu G; Feng L; Zhao Y; Zhang G; Wu Y; Ye X; Qin B; Lu J
Cell Signal; 2012 Sep; 24(9):1803-9. PubMed ID: 22609455
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and structure-activity relationship of coumarins as potent Mcl-1 inhibitors for cancer treatment.
Xia YL; Wang JJ; Li SY; Liu Y; Gonzalez FJ; Wang P; Ge GB
Bioorg Med Chem; 2021 Jan; 29():115851. PubMed ID: 33218896
[TBL] [Abstract][Full Text] [Related]
31. Discovery of a Copper-Based Mcl-1 Inhibitor as an Effective Antitumor Agent.
Lu X; Liu YC; Orvig C; Liang H; Chen ZF
J Med Chem; 2020 Sep; 63(17):9154-9167. PubMed ID: 32794745
[TBL] [Abstract][Full Text] [Related]
32. Development of Mcl-1 inhibitors for cancer therapy.
Negi A; Murphy PV
Eur J Med Chem; 2021 Jan; 210():113038. PubMed ID: 33333396
[TBL] [Abstract][Full Text] [Related]
33. Structure-Based Optimization of 3-Phenyl-
Li Y; Fan W; Gong Q; Tian J; Zhou M; Li Q; Uwituze LB; Zhang Z; Hong R; Wang R
J Med Chem; 2021 Jul; 64(14):10260-10285. PubMed ID: 34228434
[TBL] [Abstract][Full Text] [Related]
34. MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents.
Bolomsky A; Vogler M; Köse MC; Heckman CA; Ehx G; Ludwig H; Caers J
J Hematol Oncol; 2020 Dec; 13(1):173. PubMed ID: 33308268
[TBL] [Abstract][Full Text] [Related]
35. Mcl-1 inhibitors: a patent review.
Chen L; Fletcher S
Expert Opin Ther Pat; 2017 Feb; 27(2):163-178. PubMed ID: 27744724
[TBL] [Abstract][Full Text] [Related]
36. Fragment-Based Design, Synthesis, and Biological Evaluation of 1-Substituted-indole-2-carboxylic Acids as Selective Mcl-1 Inhibitors.
Wang Z; Xu W; Song T; Guo Z; Liu L; Fan Y; Wang A; Zhang Z
Arch Pharm (Weinheim); 2017 Jan; 350(1):. PubMed ID: 27911011
[TBL] [Abstract][Full Text] [Related]
37. Identification of Small-Molecule Inhibitors of the Antiapoptotic Protein Myeloid Cell Leukaemia-1 (Mcl-1).
Beekman AM; O'Connell MA; Howell LA
ChemMedChem; 2016 Apr; 11(8):840-4. PubMed ID: 26616140
[TBL] [Abstract][Full Text] [Related]
38. Mcl-1 as a "barrier" in cancer treatment: Can we target it now?
Pervushin NV; Senichkin VV; Zhivotovsky B; Kopeina GS
Int Rev Cell Mol Biol; 2020; 351():23-55. PubMed ID: 32247581
[TBL] [Abstract][Full Text] [Related]
39. Discovery of β-carboline copper(II) complexes as Mcl-1 inhibitor and in vitro and in vivo activity in cancer models.
Lu X; Liu YC; Orvig C; Liang H; Chen ZF
Eur J Med Chem; 2019 Nov; 181():111567. PubMed ID: 31401535
[TBL] [Abstract][Full Text] [Related]
40. Pro-apoptotic meiogynin A derivatives that target Bcl-xL and Mcl-1.
Desrat S; Pujals A; Colas C; Dardenne J; Gény C; Favre L; Dumontet V; Iorga BI; Litaudon M; Raphaël M; Wiels J; Roussi F
Bioorg Med Chem Lett; 2014 Nov; 24(21):5086-8. PubMed ID: 25266781
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
